NASDAQ:ESRX - Express Scripts Stock Price, Price Target & More

Get Started

$75.65 -0.70 (-0.92 %)

(As of 05/20/2018 04:00 PM ET)

Previous Close$75.65

Today's Range$75.36 - $76.83

52-Week Range$55.80 - $85.07

Volume3.76 million shs

Average Volume3.75 million shs

Market Capitalization$42.49 billion

P/E Ratio10.65

Dividend YieldN/A

Beta0.98

About Express Scripts (NASDAQ:ESRX)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores

Sub-IndustryHealth Care Services

SectorMedical

SymbolNASDAQ:ESRX

CUSIP30219G10

Webwww.express-scripts.com

Phone314-996-0900

Debt

Debt-to-Equity Ratio0.81

Current Ratio0.69

Quick Ratio0.56

Price-To-Earnings

Trailing P/E Ratio10.65

Forward P/E Ratio8.34

P/E Growth0.95

Sales & Book Value

Annual Sales$100.06 billion

Price / Sales0.42

Cash Flow$10.4924 per share

Price / Cash7.21

Book Value$32.84 per share

Price / Book2.30

Profitability

EPS (Most Recent Fiscal Year)$7.10

Net Income$4.52 billion

Net Margins4.59%

Return on Equity25.41%

Return on Assets8.28%

Miscellaneous

Employees26,600

Outstanding Shares561,720,000

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How will Express Scripts' stock buyback program work?

Express Scripts declared that its Board of Directors has initiated a share repurchase plan on Wednesday, December 20th 2017, which permits the company to repurchase 45,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

How were Express Scripts' earnings last quarter?

Express Scripts (NASDAQ:ESRX) released its quarterly earnings results on Wednesday, May, 2nd. The company reported $1.77 EPS for the quarter, topping analysts' consensus estimates of $1.76 by $0.01. The firm earned $24.77 billion during the quarter, compared to analysts' expectations of $24.80 billion. Express Scripts had a net margin of 4.59% and a return on equity of 25.41%. The company's quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.33 EPS. View Express Scripts' Earnings History.

When is Express Scripts' next earnings date?

Express Scripts is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Express Scripts.

What guidance has Express Scripts issued on next quarter's earnings?

Express Scripts issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $9.00-9.14 for the period, compared to the Thomson Reuters consensus estimate of $9.33.

What price target have analysts set for ESRX?

19 analysts have issued 12-month price objectives for Express Scripts' shares. Their forecasts range from $57.00 to $101.00. On average, they anticipate Express Scripts' share price to reach $82.3929 in the next year. View Analyst Ratings for Express Scripts.

What are Wall Street analysts saying about Express Scripts stock?

Here are some recent quotes from research analysts about Express Scripts stock:

1. According to Zacks Investment Research, "Express Scripts recently announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with Express Scripts anymore. Persistent drug pricing issue is also anticipated to affect the stock. Moreover, the company faces stiff competition, which raises concern. The company recently announced that it is getting acquired by Cigna Corporation, a global health insurance company. However, it has been benefitting from a rise in patient claims and strong customer retention. Express Scripts’ solid guidance for 2018 holds promise. Express Scripts' pharmacy-benefit management segment (PBM) coupled with recently-acquired eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. In the past six months, Express Scripts has outperformed the industry in terms of price." (5/1/2018)
2. Maxim Group analysts commented, "Cigna Corp (CI – NR) agreed to acquire ESRX for $54B, with per-share consideration of $48.75 in cash and 0.2434 shares of CI stock. CI also agreed to assume roughly $13B of net debt from ESRX." (3/8/2018)

Are investors shorting Express Scripts?

Express Scripts saw a drop in short interest in the month of April. As of April 30th, there was short interest totalling 10,485,277 shares, a drop of 13.8% from the April 13th total of 12,159,674 shares. Based on an average trading volume of 3,026,563 shares, the short-interest ratio is currently 3.5 days. Currently, 1.9% of the company's stock are short sold.

Who are some of Express Scripts' key competitors?

Some companies that are related to Express Scripts include CVS Health (CVS), Walgreens Boots Alliance (WBA), Diplomat Pharmacy (DPLO), Rite Aid (RAD), 1-800-PetMeds (PETS), Taxus Pharmaceuticals (TXSP), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Who are Express Scripts' key executives?

Express Scripts' management team includes the folowing people:

Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
Mr. James M. Havel, Exec. VP & CFO (Age 63)
Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)

Has Express Scripts been receiving favorable news coverage?

Media coverage about ESRX stock has been trending somewhat negative on Sunday, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Express Scripts earned a daily sentiment score of -0.08 on Accern's scale. They also gave media headlines about the company an impact score of 44.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Express Scripts' major shareholders?

Express Scripts' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.21%), Barrow Hanley Mewhinney & Strauss LLC (2.56%), Northern Trust Corp (1.81%), Massachusetts Financial Services Co. MA (1.28%), Dimensional Fund Advisors LP (1.15%) and LSV Asset Management (0.91%). Company insiders that own Express Scripts stock include Christine Houston, Christopher A Mcginnis, Everett Neville, Glen D Stettin, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.

Which institutional investors are selling Express Scripts stock?

ESRX stock was sold by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Barrow Hanley Mewhinney & Strauss LLC, OppenheimerFunds Inc., Manning & Napier Group LLC, BlackRock Inc., Schwab Charles Investment Management Inc., Pzena Investment Management LLC and Schroder Investment Management Group. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.

Which institutional investors are buying Express Scripts stock?

ESRX stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, State of New Jersey Common Pension Fund D, Smith Asset Management Group LP, O Shaughnessy Asset Management LLC, Mackay Shields LLC, Massachusetts Financial Services Co. MA, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Express Scripts.

How do I buy shares of Express Scripts?

Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of ESRX stock can currently be purchased for approximately $75.65.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $42.49 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]

MarketBeat Community Rating for Express Scripts (ESRX)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		701 (Vote Outperform)
Underperform Votes:		492 (Vote Underperform)
Total Votes:		1,193

MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Express Scripts (NASDAQ:ESRX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Express Scripts in the last 12 months. Their average twelve-month price target is $82.3929, suggesting that the stock has a possible upside of 8.91%. The high price target for ESRX is $101.00 and the low price target for ESRX is $57.00. There are currently 3 sell ratings, 11 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.11	2.11	2.11	2.00
Ratings Breakdown:	3 Sell Rating(s) 11 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 11 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	5 Sell Rating(s) 7 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	5 Sell Rating(s) 10 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$82.3929	$81.8214	$78.6786	$69.1667
Price Target Upside:	8.91% upside	1.33% upside	0.80% downside	13.09% upside

Express Scripts (NASDAQ:ESRX) Consensus Price Target History

Price Target History for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/17/2018	Robert W. Baird	Set Price Target	Buy	$92.00	Low
5/3/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$84.00 ➝ $83.00	High
5/3/2018	Leerink Swann	Lower Price Target	Market Perform	$90.00 ➝ $80.00	Medium
3/12/2018	Sanford C. Bernstein	Upgrade	Underperform ➝ Market Perform		Medium
3/9/2018	Wells Fargo	Upgrade	Underperform ➝ Market Perform		Low
3/8/2018	Raymond James	Upgrade	Underperform ➝ Market Perform		Low
3/8/2018	Mizuho	Set Price Target	Hold	$96.00	Low
3/8/2018	William Blair	Downgrade	Outperform ➝ Market Perform		Low
3/8/2018	Jefferies Group	Downgrade	Buy ➝ Hold	$91.00	High
3/8/2018	Maxim Group	Downgrade	Buy ➝ Hold		High
2/27/2018	Bank of America	Initiated Coverage	Underperform ➝ Underperform	$77.00	Medium
1/31/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$68.00	Low
1/12/2018	SunTrust Banks	Reiterated Rating	Buy	$95.00	Low
1/4/2018	Evercore ISI	Initiated Coverage	In ➝ In-Line	$78.00	Low
12/21/2017	Needham & Company LLC	Reiterated Rating	Hold		Low
12/4/2017	Deutsche Bank	Initiated Coverage	Buy	$75.00	High
10/9/2017	UBS	Downgrade	Market Perform ➝ Underperform		N/A
8/10/2017	Morgan Stanley	Boost Price Target	Underweight	$52.00 ➝ $57.00	Low
6/9/2017	Cowen	Reiterated Rating	Outperform	$83.00	Low
4/26/2017	Edward Jones	Downgrade	Buy ➝ Hold		High
3/29/2017	Argus	Reiterated Rating	Hold		Low
2/16/2017	Credit Suisse Group	Reiterated Rating	Buy	$85.00	N/A
2/14/2017	Oppenheimer	Reiterated Rating	Hold		N/A
6/1/2016	Wedbush	Reiterated Rating	Neutral		N/A
5/24/2016	Citigroup	Reiterated Rating	Buy		N/A

(Data available from 5/20/2016 forward)

Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart

Earnings by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Earnings Estimates

2018 EPS Consensus Estimate: $8.78
2019 EPS Consensus Estimate: $9.19

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	$1.46	$1.76	$1.69
Q2 2018	5	$1.90	$2.23	$2.14
Q3 2018	5	$2.09	$2.48	$2.35
Q4 2018	5	$2.31	$2.69	$2.59
Q1 2019	3	$1.58	$2.08	$1.83
Q2 2019	3	$2.09	$2.34	$2.21
Q3 2019	3	$2.26	$2.54	$2.43
Q4 2019	2	$2.70	$2.76	$2.73

Express Scripts (NASDAQ ESRX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/23/2018		$2.21					N/A
5/2/2018	Q1 2018	$1.76	$1.77	$24.8020 billion	$24.7694 billion	View	N/A
2/27/2018	Q4 2017	$2.09	$2.16	$25.0710 billion	$25.3790 billion	View	N/A
10/24/2017	Q3 2017	$1.90	$1.90	$25.6827 billion	$24.6834 billion	View	N/A
7/25/2017	Q2 2017	$1.71	$1.73	$25.5249 billion	$25.3475 billion	View	N/A
4/24/2017	Q1 17	$1.32	$1.33	$24.9516 billion	$24.6549 billion	View	N/A
2/14/2017	Q4 2016	$1.8660	$1.88	$26.31 billion	$24.90 billion	View	Listen
10/25/2016	Q3	$1.74	$1.74	$25.4846 billion	$25.41 billion	View	Listen
7/25/2016	Q216	$1.57	$1.57	$25.42 billion	$25.20 billion	View	Listen
4/25/2016	Q1	$1.22	$1.22	$25.20 billion	$24.80 billion	View	Listen
2/16/2016	Q4	$1.56	$1.56	$26.58 billion	$26.18 billion	View	Listen
10/27/2015	Q315	$1.44	$1.45	$26.38 million	$25.22 million	View	Listen
7/28/2015	Q215	$1.40	$1.44	$26.13 billion	$25.4540 billion	View	Listen
4/28/2015	Q115	$1.10	$1.10	$24.34 billion	$24.90 billion	View	Listen
2/23/2015	Q414	$1.38	$1.39	$25.68 billion	$26.31 billion	View	Listen
10/28/2014	Q314	$1.29	$1.29	$24.93 billion	$25.78 billion	View	Listen
7/29/2014	Q214	$1.22	$1.23	$24.42 billion	$25.1110 billion	View	Listen
4/29/2014	Q114	$1.01	$0.99	$23.81 billion	$23.6850 billion	View	Listen
2/20/2014	Q413	$1.12	$1.12	$25.49 billion	$25.78 billion	View	N/A
10/25/2013	Q313	$1.08	$1.08	$25.01 billion	$25.9160 billion	View	Listen
7/29/2013	Q2 2013	$1.10	$1.12	$25.51 billion	$26.40 billion	View	Listen
4/29/2013	Q1 2013	$0.97	$0.99	$25.55 billion	$26.0630 billion	View	Listen
2/18/2013	Q4 2012	$1.04	$1.05	$27.24 billion	$27.41 billion	View	Listen
11/5/2012	Q312	$0.99	$1.02	$27.48 billion	$27.00 billion	View	N/A
8/7/2012		$0.82	$0.88			View	N/A
5/10/2012		$0.77	$0.73			View	N/A
2/22/2012		$0.85	$0.82			View	N/A
10/25/2011		$0.77	$0.79			View	N/A
7/21/2011		$0.69	$0.71			View	N/A
4/26/2011		$0.69	$0.66			View	N/A
2/16/2011		$0.70	$0.71			View	N/A
10/27/2010	Q3 2010	$0.65	$0.65			View	N/A
7/28/2010	Q2 2010	$0.59	$0.60			View	N/A
4/28/2010	Q1 2010	$0.55	$0.55			View	N/A
2/24/2010	Q4 2009	$0.45	$0.49			View	N/A
10/28/2009	Q3 2009	$0.41	$0.40			View	N/A
7/29/2009	Q2 2009	$0.44	$0.44			View	N/A
4/29/2009	Q1 2009	$0.41	$0.43			View	N/A
2/25/2009	Q4 2008	$0.42	$0.41			View	N/A
10/30/2008	Q3 2008	$0.39	$0.41			View	N/A
7/30/2008	Q2 2008	$0.36	$0.38			View	N/A
4/29/2008	Q1 2008	$0.34	$0.35			View	N/A
2/21/2008	Q4 2007	$0.32	$0.34			View	N/A

(Earnings results data provided by Zacks Investment Research)

Express Scripts (NASDAQ:ESRX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 88.20%

Insider Trading History for Express Scripts (NASDAQ:ESRX)

Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2018	Christine Houston	Insider	Sell	19,889	$76.69	$1,525,287.41
3/1/2018	Everett Neville	VP	Sell	4,895	$75.26	$368,397.70
1/11/2018	Glen D Stettin	VP	Sell	3,449	$81.00	$279,369.00	33,715
1/2/2018	Glen D Stettin	VP	Sell	3,448	$76.00	$262,048.00
12/15/2017	Christine Houston	VP	Sell	10,104	$70.08	$708,088.32	87,400
11/1/2017	Phyllis S. Anderson	VP	Sell	643	$62.37	$40,103.91
10/31/2017	Timothy C Wentworth	CEO	Buy	8,000	$61.13	$489,040.00	98,628
9/11/2017	Woodrow A Myers Jr	Director	Sell	3,900	$63.93	$249,327.00	11,500
9/8/2017	Phyllis S Anderson	VP	Sell	578	$63.13	$36,489.14	10,530
8/23/2017	Everett Neville	VP	Sell	1,163	$61.48	$71,501.24	18,232
5/19/2017	Phyllis S Anderson	VP	Sell	1,100	$60.08	$66,088.00	11,108
3/1/2017	Everett Neville	SVP	Sell	2,352	$70.16	$165,016.32	11,287
1/3/2017	Everett Neville	VP	Sell	1,123	$69.41	$77,947.43	12,712
9/14/2016	Woodrow A Myers Jr	Director	Sell	12,036	$70.40	$847,334.40	14,918
9/12/2016	Christopher A Mcginnis	VP	Sell	1,785	$70.77	$126,324.45	4,955
5/10/2016	Everett Neville	VP	Sell	800	$74.11	$59,288.00	13,835
4/29/2016	Mahon Thomas P Mac	Director	Sell	5,482	$73.93	$405,284.26	55,689
3/10/2016	Christopher A Mcginnis	VP	Sell	579	$68.56	$39,696.24	6,508
3/7/2016	Phyllis S Anderson	VP	Sell	614	$71.14	$43,679.96	4,346
2/29/2016	Everett Neville	VP	Sell	4,323	$71.00	$306,933.00	11,126
6/9/2015	Gary Wimberly	VP	Sell	1,644	$87.14	$143,258.16
6/1/2015	Gary Wimberly	VP	Sell	46,069	$86.15	$3,968,844.35
3/2/2015	Glen D Stettin	VP	Sell	2,674	$84.39	$225,658.86
2/25/2015	Glen D Stettin	VP	Sell	27,603	$87.55	$2,416,642.65
12/2/2014	Keith J Ebling	VP	Sell	10,000	$84.25	$842,500.00
12/1/2014	Steven B Miller	VP	Sell	4,896	$83.57	$409,158.72
11/28/2014	Glen D Stettin	VP	Sell	10,800	$82.96	$895,968.00
11/17/2014	John O Parker	Director	Sell	25,822	$78.75	$2,033,482.50
11/7/2014	Maura C Breen	Director	Sell	13,128	$77.80	$1,021,358.40
9/5/2014	Edward B Ignaczak	EVP	Sell	9,886	$75.28	$744,218.08
8/28/2014	Seymour Sternberg	Director	Sell	15,508	$74.12	$1,149,452.96
8/25/2014	Keith J Ebling	VP	Sell	10,000	$75.50	$755,000.00
8/5/2014	Gary G Benanav	Director	Sell	12,694	$70.82	$898,989.08
8/5/2014	Sara E Wade	VP	Sell	20,000	$70.44	$1,408,800.00
8/4/2014	David A Norton	VP	Sell	1,276	$71.02	$90,621.52
8/1/2014	Maura C Breen	Director	Sell	12,694	$69.94	$887,818.36
6/13/2014	George Paz	CEO	Sell	681,508	$71.21	$48,530,184.68
3/11/2014	Keith Ebling	VP	Sell	25,721	$78.69	$2,023,985.49	22,222
3/10/2014	Patrick Mcnamee	COO	Sell	68,425	$78.28	$5,356,309.00	12,421
3/10/2014	Steven Miller	VP	Sell	12,664	$77.96	$987,285.44	21,417
3/7/2014	Keith Ebling	VP	Sell	295,367	$77.29	$22,828,915.43	28,460
1/9/2014	Nicholas Lahowchic	Director	Sell	7,650	$72.00	$550,800.00	24,903
12/26/2013	Nicholas Lahowchic	Director	Sell	12,694	$70.00	$888,580.00	24,903
11/5/2013	Mahon Thomas Mac	Director	Sell	10,251	$63.20	$647,863.20	39,881
9/9/2013	Maura C Breen	Director	Sell	10,527	$64.12	$674,991.24
9/4/2013	Woodrow Myers, Jr.	Director	Sell	7,128	$64.66	$460,896.48	9,698
7/19/2013	Nicholas Lahowchic	Director	Sell	20,377	$66.26	$1,350,180.02
6/11/2013	Woodrow A Myers Jr	Director	Sell	1,750	$62.57	$109,497.50
5/28/2013	Woodrow A Myers Jr	Director	Sell	2,000	$63.75	$127,500.00
5/15/2013	Jeffrey Hall	CFO	Sell	13,307	$61.13	$813,456.91
5/8/2013	Woodrow A Myers Jr	Director	Sell	13,462	$61.22	$824,143.64
5/1/2013	Keith J Ebling	EVP	Sell	59,494	$59.58	$3,544,652.52
4/30/2013	Patrick Mcnamee	COO	Sell	271,972	$59.65	$16,223,129.80
3/14/2013	Mahon Thomas P Mac	Director	Buy	5,000	$59.58	$297,900.00
9/4/2012	Jeffrey Hall	CFO	Sell	75,000	$62.81	$4,710,750.00
8/8/2012	Edward B Ignaczak	EVP	Sell	115,466	$59.33	$6,850,597.78

(Data available from 1/1/2013 forward)

Express Scripts (NASDAQ ESRX) News Headlines

Source:

Date	Headline
	Express Scripts (ESRX) Expected to Announce Quarterly Sales of $25.34 Billion www.americanbankingnews.com - May 20 at 2:12 AM
	$2.23 EPS Expected for Express Scripts (ESRX) This Quarter www.americanbankingnews.com - May 18 at 7:29 PM
	Notable Friday Option Activity: ACXM, ESRX, ADBE www.nasdaq.com - May 18 at 5:58 PM
	U.S. FDA approves Amgen drug for prevention of migraines finance.yahoo.com - May 18 at 9:04 AM
	Express Scripts (ESRX) Given a $92.00 Price Target at Robert W. Baird www.americanbankingnews.com - May 17 at 2:59 PM
	Express Scripts to remain in St. Louis County, filing says finance.yahoo.com - May 16 at 6:03 PM
	Express Scripts (ESRX) Short Interest Update www.americanbankingnews.com - May 13 at 1:40 AM
	Express Scripts (ESRX) Downgraded by BidaskClub to Sell www.americanbankingnews.com - May 11 at 8:05 PM
	Trump assails high drug prices, avoids direct hit on industry finance.yahoo.com - May 11 at 6:24 PM
	Express Scripts and CVS among those gaining after Trump speech seekingalpha.com - May 11 at 3:52 PM
	The Trump administration has a little-known practice in the pharma industry in its crosshairs (ESRX) www.msn.com - May 11 at 8:25 AM
	Innovative Value-based SafeGuardRx® Program Delivers Better Care at Lower Cost for Express Scripts' Patients and Plan Sponsors finance.yahoo.com - May 10 at 5:58 PM
	ESRX Makes Notable Cross Below Critical Moving Average www.nasdaq.com - May 8 at 6:00 PM
	Express Scripts Vulnerable Ahead Of President Trump's New Policy Outlines seekingalpha.com - May 8 at 8:00 AM
	How Tampa Bay’s startup community compares to the rest of the world finance.yahoo.com - May 7 at 8:04 AM
	Equities Analysts Offer Predictions for Express Scripts' FY2018 Earnings (ESRX) www.americanbankingnews.com - May 7 at 4:01 AM
	Q3 2018 EPS Estimates for Express Scripts Reduced by Analyst (ESRX) www.americanbankingnews.com - May 7 at 3:23 AM
	Q2 2018 EPS Estimates for Express Scripts Reduced by Jefferies Group (ESRX) www.americanbankingnews.com - May 7 at 2:16 AM
	Express Scripts to Post Q2 2018 Earnings of $2.23 Per Share, Leerink Swann Forecasts (ESRX) www.americanbankingnews.com - May 7 at 2:16 AM
	Express Scripts (ESRX) Downgraded to "Hold" at BidaskClub www.americanbankingnews.com - May 5 at 12:29 AM
	'60 Minutes' report to focus on price of Mallinckrodt dru... finance.yahoo.com - May 4 at 5:51 PM
	Oppenheimer Comments on Express Scripts' Q2 2018 Earnings (ESRX) www.americanbankingnews.com - May 4 at 8:50 AM
	Q2 2018 Earnings Estimate for Express Scripts Issued By William Blair (ESRX) www.americanbankingnews.com - May 4 at 8:50 AM
	Express Scripts (ESRX) PT Lowered to $83.00 www.americanbankingnews.com - May 4 at 12:23 AM
	Express Scripts (ESRX) PT Lowered to $80.00 www.americanbankingnews.com - May 3 at 8:34 PM
	Cigna first quarter profit beats but shares drop on Express Scripts worries www.reuters.com - May 3 at 5:39 PM
	Cigna CEO: There's a lot of noise around regulatory concern of Express Scripts deal www.cnbc.com - May 3 at 1:21 PM
	Inside Rx, a Prescription Savings Program from Express Scripts, Expands List of Discounted Brand-Name Medications www.prnewswire.com - May 3 at 9:36 AM
	Health insurer Cigna quarterly profit rises 53 pct finance.yahoo.com - May 3 at 8:00 AM
	Health insurer Cigna profit beats estimates finance.yahoo.com - May 3 at 8:00 AM
	$24.76 Billion in Sales Expected for Express Scripts (ESRX) This Quarter www.americanbankingnews.com - May 3 at 4:20 AM
	ValuEngine Lowers Express Scripts (ESRX) to Hold www.americanbankingnews.com - May 2 at 11:23 PM
	Express Scripts (ESRX) Announces Earnings Results www.americanbankingnews.com - May 2 at 7:32 PM
	Express Scripts (ESRX) Updates FY18 Earnings Guidance www.americanbankingnews.com - May 2 at 6:08 PM
	EXPRESS SCRIPTS HOLDING COMPANY www.finanznachrichten.de - May 2 at 5:50 PM
	Express Scripts Q1 top line flat; earnings up 14%; cash flow up 51% seekingalpha.com - May 2 at 5:50 PM
	Express Scripts Updates FY18 Adj. EPS Guidance - Quick Facts www.nasdaq.com - May 2 at 5:50 PM
	Express Scripts Announces 2018 First Quarter Results finance.yahoo.com - May 2 at 5:50 PM
	Express Scripts Ranked as a Top 50 Inclusive company by DiversityInc finance.yahoo.com - May 2 at 5:50 PM
	Express Scripts: 1Q Earnings Snapshot finance.yahoo.com - May 2 at 5:50 PM
	Express Scripts shares slip after revenue miss, lowered outlook finance.yahoo.com - May 2 at 5:50 PM
	Express Scripts (ESRX) Downgraded to Sell at Zacks Investment Research www.americanbankingnews.com - May 1 at 12:26 PM
	$1.76 EPS Expected for Express Scripts (ESRX) This Quarter www.americanbankingnews.com - May 1 at 8:21 AM
	Regeneron/Sanofi to cut price of heart drug in Express Scripts deal finance.yahoo.com - May 1 at 8:04 AM
	Regeneron And Express Scripts Reach A Deal On Embattled Cholesterol Drug finance.yahoo.com - May 1 at 8:04 AM
	[$$] Sanofi slashes price of wannabe-blockbuster cholesterol drug finance.yahoo.com - May 1 at 8:04 AM
	Regeneron and Express Scripts announce exclusive pricing ... finance.yahoo.com - May 1 at 8:04 AM
	Sanofi/Regeneron cut Praluent drug price in Express Scripts deal finance.yahoo.com - May 1 at 8:04 AM
	Express Scripts (ESRX) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - April 30 at 11:36 AM
	ValuEngine Upgrades Express Scripts (ESRX) to Buy www.americanbankingnews.com - April 26 at 2:04 PM

Express Scripts (NASDAQ:ESRX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement

Express Scripts (NASDAQ ESRX) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff